Caroline Stokke

Latest

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
The Prognostic Value of [(18)F]FDG PET/CT Texture Analysis Prior to Transplantation for Unresectable Colorectal Liver Metastases.
Do We Need Dosimetry for Optimization of Theranostics in CNS Tumors?
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
EANM Guidance Document: Dosimetry for First-in-Human Studies and Early Phase Clinical Trials.
Implementation of Dosimetry for Molecular Radiotherapy; Results from a European Survey.
Time-Activity Data Fitting in Molecular Radiotherapy: Methodology and Pitfalls.
EFOMP Policy Statement NO. 19: Dosimetry in Nuclear Medicine Therapy - Molecular Radiotherapy.
Use of Ionizing Radiation in a Norwegian Cohort of Children with Congenital Heart Disease: Imaging Frequency and Radiation Dose for the Health Effects of Cardiac Fluoroscopy and Modern Radiotherapy in Pediatrics (HARMONIC) Study.
Intensifying Treatment in PET-positive Multiple Myeloma Patients after Upfront Autologous Stem Cell Transplantation.
Imaging of (212)Pb in Mice with a Clinical SPECT/CT.
Optimized SPECT Imaging of (224)Ra α-Particle Therapy by (212)Pb Photon Emissions.
Results from an EANM Survey on Time Estimates and Personnel Responsible for Main Tasks in Molecular Radiotherapy Dosimetry.
EANM Enabling Guide: How to Improve the Accessibility of Clinical Dosimetry.
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An Update.
Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE.
Scar Imaging in the Dyssynchronous Left Ventricle: Accuracy of Myocardial Metabolism by Positron Emission Tomography and Function by Echocardiographic Strain.
Radiation Safety Considerations for the Use of Radium-224-Calciumcarbonate-Microparticles in Patients with Peritoneal Metastasis.
Comparison of [(18)F]Fluciclovine and [(18)F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients.
FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent Non-Hodgkin Lymphoma-Are We Hitting the Target?
Radionuclides for Targeted Therapy: Physical Properties.
Quantitative SPECT/CT Imaging of Lead-212: A Phantom Study.
EANM Dosimetry Committee Recommendations for Dosimetry of 177Lu-labelled Somatostatin-Receptor- and PSMA-targeting Ligands.
Evaluation of Semi-Quantitative Measures of (18)F-flutemetamol PET for the Clinical Diagnosis of Alzheimer's Disease.
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?
EANM Dosimetry Committee Series on Standard Operational Procedures: A Unified Methodology for (99m)Tc-MAA Pre- and (90)Y Peri-Therapy Dosimetry in Liver Radioembolization with (90)Y Microspheres.
Myelosuppression in Patients Treated with (177)Lutetium-lilotomab Satetraxetan Can Be Predicted with Absorbed Dose to the Red Marrow as the Only Variable.
Left Ventricular Regional Glucose Metabolism in Combination with Septal Scar Extent Identifies CRT Responders.
FDG PET/CT Parameters and Correlations with Tumor-Absorbed Doses in a Phase 1 Trial of (177)Lu-lilotomab Satetraxetan for Treatment of Relapsed Non-Hodgkin Lymphoma.
Phase 1/2a Study of 177Lu-lilotomab Satetraxetan in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
EANM Dosimetry Committee Series on Standard Operational Procedures for Internal Dosimetry for (131)I mIBG Treatment of Neuroendocrine Tumours.
Regional Myocardial Work by Cardiac Magnetic Resonance and Non-Invasive Left Ventricular Pressure: A Feasibility Study in Left Bundle Branch Block.
Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Amyloid-β PET-Correlation with Cerebrospinal Fluid Biomarkers and Prediction of Alzheimer´s Disease Diagnosis in a Memory Clinic.
The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass-Normalized SUV in Oncologic (18)F-FDG PET/CT.
Pre-Dosing with Lilotomab Prior to Therapy with (177)Lu-lilotomab Satetraxetan Significantly Increases the Ratio of Tumor to Red Marrow Absorbed Dose in Non-Hodgkin Lymphoma Patients.
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate (177)Lu-Lilotomab Satetraxetan.
Respiratory Motion during (90)Yttrium PET Contributes to Underestimation of Tumor Dose and Overestimation of Normal Liver Tissue Dose.
Variations in the Practice of Molecular Radiotherapy and Implementation of Dosimetry: Results from a European Survey.
Dosimetry-Based Treatment Planning for Molecular Radiotherapy: A Summary of the 2017 Report from the Internal Dosimetry Task Force.
Combining Radioiodine and External Beam Radiation Therapy: The Potential of Integrated Treatment Planning for Differentiated Thyroid Cancer.
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.